Nintedanib Soft Gelatin Capsules 150 mg: Uses, Benefits & Precautions
NINTEPRIDE 150 contains Nintedanib Soft Gelatin Capsules 150 mg and is marketed by Steris Healthcare. Nintedanib is a prescription medicine belonging to the tyrosine kinase inhibitor class and is used for specific chronic and progressive lung conditions. It works by inhibiting signaling pathways involved in abnormal growth and scarring of lung tissue.
Nintedanib treatment requires medical supervision because the medicine can affect the liver and may cause gastrointestinal and other adverse effects. The appropriate indication, dosage and duration should always be determined by a qualified healthcare professional.
What is NINTEPRIDE 150 Used For?
Nintedanib Soft Gelatin Capsules 150 mg may be prescribed for adults with certain fibrosing interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), progressive fibrosing ILDs and systemic-sclerosis-associated interstitial lung disease, depending on the clinical indication and applicable prescribing guidance.
These conditions can involve progressive scarring of lung tissue, which may reduce lung function over time. Nintedanib does not remove established lung scarring, but treatment can help slow the rate of decline in lung function in appropriately selected patients.
NINTEPRIDE 150 should be used only for an indication diagnosed and monitored by a healthcare professional.
Why is Nintedanib 150 mg Important?
Progressive fibrotic lung diseases can gradually impair breathing capacity and may significantly affect daily activities and quality of life. Abnormal signaling involving growth factors such as vascular endothelial growth factor, fibroblast growth factor and platelet-derived growth factor contributes to processes involved in fibrosis.
Nintedanib targets these signaling pathways. By inhibiting relevant receptor tyrosine kinases, it can reduce signaling associated with fibroblast activity and fibrotic disease progression.
For eligible patients, this mechanism provides an important disease-modifying approach rather than simply treating symptoms such as breathlessness or cough.
Key Benefits
What are the Benefits?
When prescribed for an appropriate indication, NINTEPRIDE 150 may provide important clinical benefits, including:
Helps slow the decline of lung function associated with certain progressive fibrotic lung diseases.
Used in the management of idiopathic pulmonary fibrosis.
May be used for certain progressive fibrosing interstitial lung diseases.
May be prescribed for systemic-sclerosis-associated interstitial lung disease.
Targets multiple growth-factor signaling pathways involved in fibrosis.
Provides a disease-modifying treatment option for appropriately selected patients.
Nintedanib is not a cure for pulmonary fibrosis and does not immediately reverse existing lung damage. Its primary role is to slow disease progression when clinically appropriate.
Side Effects
Like other prescription medicines, Nintedanib 150 mg can cause side effects. The most commonly reported adverse effect is diarrhea.
Other possible side effects include:
Nausea
Vomiting
Abdominal pain
Reduced appetite
Weight loss
Headache
Tiredness
Increased liver enzymes
Skin-related reactions
Maintaining adequate hydration is particularly important if diarrhea or vomiting occurs.
Serious Side Effects
Seek prompt medical attention if you experience:
Severe or persistent diarrhea with dehydration
Significant or unexplained bleeding
Severe abdominal pain
Yellowing of the skin or eyes
Dark urine
Severe allergic reaction
Difficulty breathing
Significant chest pain
Symptoms suggesting a blood clot or cardiovascular event
Nintedanib can cause liver enzyme elevations and, rarely, serious liver injury. It can also increase bleeding risk, particularly in patients taking anticoagulant or other medicines that affect bleeding.
Available Substitute
There is no universal substitute for NINTEPRIDE 150 because treatment depends on the specific type of interstitial lung disease, disease severity, comorbidities and individual response.
A specialist may consider:
Other nintedanib formulations or brands
Pirfenidone for selected patients with idiopathic pulmonary fibrosis
Other disease-specific treatments for particular interstitial lung diseases
Immunomodulatory treatment in selected conditions
A substitute should not be chosen solely based on price or brand availability. Patients should consult their pulmonologist or treating specialist before changing antifibrotic treatment.
Dosage Guidelines
The commonly recommended adult dose of nintedanib for many approved fibrotic lung indications is 150 mg twice daily, approximately 12 hours apart, but the exact regimen should be confirmed by the prescribing healthcare professional.
General administration guidance includes:
Take the capsule exactly as prescribed.
Take it with food.
Swallow the soft gelatin capsule whole with liquid.
Do not chew, crush or open the capsule.
Maintain adequate hydration, particularly if diarrhea occurs.
If a dose is missed, follow the prescribed missed-dose instructions rather than taking an extra dose.
Dose reduction or temporary interruption may be required if significant adverse effects occur.
The dose may be reduced to 100 mg twice daily or treatment may be temporarily interrupted in certain circumstances under medical supervision.
Precautions & Warnings
Before starting Nintedanib Soft Gelatin Capsules 150 mg, inform your healthcare professional if you have:
Liver disease
Kidney impairment
A history of bleeding
Cardiovascular disease
A history of blood clots
Recent major surgery
Gastrointestinal disorders
A history of gastrointestinal perforation
Known allergy to nintedanib or formulation ingredients
Mechanism of Action
Nintedanib is an intracellular tyrosine kinase inhibitor with antifibrotic activity.
It inhibits signaling through several receptor tyrosine kinases, including receptors associated with:
Fibroblast growth factor (FGF)
Platelet-derived growth factor (PDGF)
It also inhibits certain non-receptor tyrosine kinases involved in cellular signaling.
These pathways contribute to processes such as fibroblast activation, proliferation, migration and extracellular-matrix production. Excessive activity of these processes is involved in the development and progression of pulmonary fibrosis.
By inhibiting these signaling pathways, nintedanib helps reduce the activity associated with abnormal fibrotic remodeling of lung tissue.
The result is not immediate removal of existing scar tissue. Rather, nintedanib is intended to slow the progression of lung-function decline in appropriately selected patients.
How to Use
For appropriate use of NINTEPRIDE 150:
Take the medicine exactly as prescribed by your specialist.
Take capsules with food.
Swallow capsules whole.
Do not crush or chew them.
Monitor for persistent diarrhea.
Maintain adequate hydration.
Attend scheduled liver-function tests.
Inform your healthcare professional about all medicines and supplements.
Report unusual bleeding or symptoms of liver problems promptly.
Follow your pulmonologist's recommendations for monitoring lung function.
Do not discontinue antifibrotic therapy without discussing it with your treating specialist.
Conclusion
NINTEPRIDE 150, containing Nintedanib Soft Gelatin Capsules 150 mg, is marketed by Steris Healthcare and is used under specialist supervision for certain progressive fibrotic lung diseases, including appropriately diagnosed idiopathic pulmonary fibrosis and other approved interstitial lung disease indications.
Nintedanib works by inhibiting multiple tyrosine kinase signaling pathways associated with growth-factor activity and fibrosis. By reducing these signaling processes, it can help slow the decline of lung function in eligible patients.
Diarrhea, nausea, abdominal discomfort and liver enzyme elevations are among the important adverse effects to monitor. Liver-function monitoring, management of gastrointestinal effects and attention to bleeding and cardiovascular risks are important aspects of treatment.
NINTEPRIDE 150 should be taken only under appropriate medical supervision, with the dose and treatment duration individualized according to the patient's condition, response and tolerability.
Comments
Post a Comment